Aurelia de Pauw

Corporate Officer/Principal at TETRA BIO-PHARMA INC.

Health Technology

Consumer Services

Profile

Aurelia de Pauw is currently the Director at TALLC Corp., Inc. and the Vice President-Clinical Programs & Medical Affairs at Tetra Bio-Pharma, Inc. She graduated from Faculté Universitaire des Sciences Agronomiques de Gembloux with a graduate degree in 2005 and received her doctorate degree from Université de Namur ASBL in the same year.

Aurelia de Pauw active positions

Companies	Position	Start
TETRA BIO-PHARMA INC.	Corporate Officer/Principal	2018-09-30
TALLC Corp., Inc. TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada.	Director/Board Member	-

All active positions of Aurelia de Pauw

Training of Aurelia de Pauw

Faculté Universitaire des Sciences Agronomiques de Gembloux	Graduate Degree
Université de Namur ASBL	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Aurelia de Pauw's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
TETRA BIO-PHARMA INC.	Health Technology

Private companies	1
TALLC Corp., Inc. TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada.	Health Technology